Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Penn researchers identify secondary pathway for survival of cancer cells

17.07.2003


Discovery may lead to targeted therapies to interrupt cancer development


Principal investigator Craig Thompson, MD (right), shows immunologist Casey Fox, PhD, images of gel results (dark bands) of surviving cancer cells when enzyme Pim-2 is present. Their latest research into the origins of cancer is published in the August 1 edition of Genes & Development. Abramson Family Cancer Research Institute, University of Pennsylvania (2003)



(Philadelphia, PA) – Researchers at the Abramson Family Cancer Research Institute at the University of Pennsylvania have determined that a key enzyme, Pim-2, is responsible for the survival of cancer cells. The finding – which will appear in the August 1 edition of the journal Genes & Development – represents an important advance in understanding why cancer cells survive in the body (working against the body’s natural immune system), before growing into tumors. It also answers a 20-year-old question as to the purpose of Pim-2, an enzyme present in high concentrations in many tumors, but left unstudied to this time; and it equates Pim-2 with another, more commonly studied survival pathway, the Akt-enzyme pathway.

"This finding is important because it shows, for the first time, how Pim-2 works and its key role in cancer cell survival," said Craig Thompson, MD, Principal Investigator of the study and Scientific Director of the Abramson Family Cancer Research Institute (AFCRI). "Up until now, predominant thinking has looked to the Akt pathway as the primary pathway for cancer cells. Now we know that Pim-2 plays an equally important role – and it is as much of a cancer-promoting gene, or oncogene, as Akt.


"Our next step is to try and manipulate the action of Pim-2, so that we can interfere with the survival of cancer cells," said Thompson. "Ultimately, the hope is that this could lead to new, targeted therapies for killing cancer cells before they turn into deadly tumors that can spread elsewhere in the body."

Pim-2 was originally identified, in 1984, as a serine/threonine kinase, one of several hundred principal oncogenes under investigation for their role in cancer cell survival and growth. Its mutated form has been observed in high quantities in cases of prostate cancer, leukemia and multiple myeloma. Close to 50 kinases are thought to play a key role in cancer progression. Through a process of elimination, scientists test each oncogene for its role or function in cancer progression, manipulating each gene, to see which changes, called mutations, allow the cell to live, and which ones let the cell die.

In the presence of Pim-2, sixty per cent of cancer cells survived attempts to starve or kill the cell. Cancer cells survived for the maximum duration in the study – up to three weeks – with Pim-2 present, regardless of whether or not growth factor (food for the cell) was present. Only when both the Akt pathway and Pim-2 pathway were dysregulated (no longer functioning inside the cell), were cancerous cells unable to survive and died. The Akt pathway is well studied because it plays many roles in cancer progression, including a key role in cancer cell survival.

Both Pim-2 and Akt survival pathways were found to operate independently; Pim-2 was not activated by any of the Akt pathway regulating enzymes – PI3K, HSP-90 and TOR. While Akt interacts with other enzymes to promote cell survival, the function of Pim-2 is independent, with no other enzymes required. The pathways were shown to be distinct by their response to the antibiotic rapamycin: Akt is sensitive to rapamycin and Pim-2 is not. Rapamycin is a commonly used drug for treatment of transplant patients, it restrains the body’s immune response from rejecting foreign growths, such as a new organ. Pim-2 overcomes this potent inhibitor of cell survival.

While these pathways appeared distinct, they are not completely different and both have some common actions. One factor shared by both pathways is a phosphorylated "off signal" suppressor protein called 4E-BP1. Suppressor genes prevent the cancer cell from growing, so when turned "off", the cell can grow.

Exposing the role of Pim-2 was accomplished through the latest technology for cancer research, a micro-array analysis of RNA in the immune systems of mice.

Penn scientists focused their research on the question of why cancer cells survive – and not simply removed from the body by the immune system. For tumor cells to grow, they must have the ability to ignore "death signals" that would cause them to die, and not promote cancer. Pim-2 had been shown as an important gene in causing tumors in mouse experiments, and was also present in large amounts in tumors. Over-production of Pim-2 allows the cells to ignore or become insensitive to boosters of the immune system, such as the antibiotic rapamycin.

The study took two years to complete (mid-2000 to mid-2002). Funding was provided through grants from the National Cancer Institute and the AFCRI.

David March | EurekAlert!
Further information:
http://www.uphs.upenn.edu/news

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>